期刊文献+

转化医学模式下疾病标志物的挖掘 被引量:3

The mining of the disease markers in translational medicine research
下载PDF
导出
摘要 疾病标志物是用于疾病的鉴定、早期诊断及预防、治疗过程中的监控。疾病标志物的挖掘包括发现、验证、确认与应用四大核心环节,寻找和发现有价值的疾病标志物已经成为目前研究的一个重要热点。传统的疾病标志物发展途径已渐渐满足不了当今研究的需要,而填补这一从实验室到临床的鸿沟要依靠转化医学模式的发展成果,即转化医学模式下的疾病标志物挖掘方式才是最适用的。本文介绍了国内外一些转化医学在疾病标志物发现与验证确认过程中方法策略的运用,如与标志物发现紧密相关的分子分析、成像技术等,转化医学分析方法中的生物分析验证和临床验证阶段,从而进一步指出与转化医学相结合的疾病标志物的挖掘能够更好地解决标志物实验室发现与临床应用之间过渡研究的难题。 Disease markers are defined to identify, early diagnose and monitor in the prevention and treatment of disease. The mining of the disease markers includes four steps which are discovery, validation, confirmation and application. To seek and discover the valuable disease markers has been a hotspot in this field nowadays. The traditional way of disease markers development has been not gradually satisfy the need of the research, and the development of the translational medicine can fill the gap from bench to bedside, namely, the mining of the disease markers in translational medicine research is the most suitable as a solution. In this paper some methods and strategies of translational medicine are introduced, which are applied in the process of discovery, validation and confirmation of disease markers at home and abroad, such as molecular analysis and imaging techniques closely related to the discovery of markers, biological analysis validation and clinical validation phase in the translational medicine analysis methods. Thus it is further pointed out that the combination between translational medicine and the mining of disease markers could solve the problem of the transition between markers laboratory findings and clinical application research.
出处 《分子诊断与治疗杂志》 2014年第2期127-133,共7页 Journal of Molecular Diagnostics and Therapy
基金 十二五国家高技术研究发展计划(863计划)(2012AA020205)
关键词 疾病标志物 转化医学 发现 验证 确认 应用 Disease marker Translational medicine Discovery Validation Confirmation Application
  • 相关文献

参考文献30

  • 1杜海燕,林阳.转化医学研究将推动个体化药品开发[J].药品评价,2011,8(16):4-7. 被引量:2
  • 2Cohen M M, Diamond J M. Medical research. Are we losing the war on cancer[J]. Nature, 1986, 323(6088): 488-489.
  • 3Adams J U. Building the bridge from bench to bedside[J]. Nat Rev Drug Discov, 2008, 7(6): 463-464.
  • 4王敏,刘妮波,张燕舞,张玢,李阳,许培扬.从文献分析角度聚焦国际转化医学研究发展及现状[J].基础医学与临床,2011,31(10):1168-1175. 被引量:17
  • 5Ciccimaro E, Blair I A. Stable-isotope dilution LC-MS for quantitative biomarker analysis[J]. Bioanalysis, 2010, 2(2):311-341.
  • 6侯淑玲,张巧花,王军,贺建霞,郭素堂.应用表面增强激光解吸电离-飞行时间-质谱技术筛选淋巴瘤患者血清特异性生物标志物[J].白血病.淋巴瘤,2011,20(11):672-675. 被引量:4
  • 7Hossain M, Kaleta D T, Robinson E W, et al. Enhanced sensitivity for selected reaction monitoring mass spectrometry-based targeted proteomics using a dual stage electrodynamic ion funnel interface[J]. Mol Cell Proteomics, 2011, 10(2): M000062-MCP201.
  • 8Dunn W B, Bailey N J, Johnson H E. Measuring the metabolome: current analytical technologies[J]. Analyst, 2005,130(5):606-625.
  • 9Maclntyre D A, Jimenez B, Lewintre E, et al. Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups[J]. Leukemia, 2010, 24(4): 788-797.
  • 10Sreekumar A, Poisson L M, Rajendiran Metabolomic profiles delineate potential role T M, et al. for sarcosine in prostate cancer progression[J]. Nature, 2009, 457(7231) 910-914.

二级参考文献67

  • 1濮月华,孙海欣,边立衡,郑华光.欧洲卒中战略宣言——赫尔辛堡2006[J].中国卒中杂志,2007,2(7):554-562. 被引量:3
  • 2Peri S, Navarro J, Kristiansen T, Amanchy R, Surendranath V, Muthusamy B, Gandhi T, Chandrika K, Deshpande N, Suresh S, Rashmi B, Shanker K, Padma N, Niranjan V, Harsha H, Talreja N, Vrushabendra B, Ramya M, Yatish A, Joy M, Shivashankar H, Kavitha M, Menezes M, Choudhury D, Ghosh N, Saravana R, Chandran S, Mohan S, Jonnalagadda C, Prasad C, Kumar-Sinha C, Deshpande K, Pandey A: Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res 2004, (32 Database):497-501.
  • 3Han-Yu Chuang, Eunjung Lee, Yu-Tsueng Liu, Doheon Lee and Trey Ideker. Network-based classification of breast cancer metastasis. Molecular Systems Biology. 2007;3:140.
  • 4Oswald P , Souery D, Kasper S, Lecrubier Y, Montgomery S, Wyckaert S, Zohar J, Mendlewicz J. Current issues in bipolar disorder:, a critical review. European Neuropsychopharmacology. 2007 vol. 17(no. 11).
  • 5Geraghty J. Adenomatous polyposis coli and translational medicine [ J ]. Lancet, 1996,17 : 348 - 422.
  • 6Marincola FM. Translational Medicine: A two-way road [ J ]. Transl Med, 2003,1 : 1.
  • 7Mckinney GR,Stavely HE. From bench to bedside: the biologist in drug development[ J]. Bioscience, 1966,16:683 - 687.
  • 8Phagocytes and the "bench-bedside interface" [ J ]. N Engl J Med, 1968, 278 : 1014 - 1016.
  • 9Wolf S. The real gap between bench and bedside[ J]. N Engl J Med, 1974, 290 : 802 - 803.
  • 10Merz B. Nobelists take genetics from bench to bedside [ J]. JAMA,1985, 254:3161.

共引文献24

同被引文献32

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部